A patient with stage IV lung adenocarcinoma that was negative for ALK rearrangement but positive for high-level MET amplification (MET/CEP7 ratio of >5.0) started treatment with crizotinib at a dose of 250 mg twice a day [57]. The gene discussed is MET; the disease is lung adenocarcinoma.